Key Takeaways
- • CVC Capital Partners' Fund VII holds a 47% stake in Milan-listed drugmaker Recordati SpA, acquired through a 2018 deal with the founding family.
- • According to Bloomberg News, the fund explored sale talks in 2024, but no formal transaction materialized.
- • The Recordati situation illustrates a broader private equity pattern: selling maturing assets to another buyout fund, often one run by the same firm, when third-party buyers are scarce.
- • The story frames such continuation-style sales as a self-dealing concern for the industry, with the article's headline pegging the broader issue at $12 billion.
Summary
CVC's Fund VII holds a 47% stake in Recordati, the Milan-listed drugmaker, following a 2018 transaction with the company's founding family. According to the article, the investment has performed well, but a clean exit has proved elusive. Bloomberg News reported that there were sale talks in 2024, though no formal transaction materialized.
The Recordati case highlights the structural tension inherent in such arrangements. When a fund seeks to exit an asset and the buyer is a sister vehicle under the same management, questions arise about pricing, conflicts of interest and whether limited partners are receiving a fair outcome. The headline of the original piece frames the broader issue as a $12 billion self-dealing problem, though the primary source excerpt available here does not provide a detailed breakdown of that figure.
For institutional investors, the episode underscores the liquidity and governance considerations that accompany single-asset or concentrated stakes held over extended periods, and the scrutiny that intra-firm secondary transactions can attract.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.